Clinical Trial

ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues

Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, and CRP.This…

1 year ago

Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting

TURKU, Finland and BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage…

1 year ago

InvestmentPitch Media Video Discusses FSD Pharma’s Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin Harrington

VANCOUVER, British Columbia, Sept. 22, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biotechnology company building a…

1 year ago

Humacyte to Present at the Cantor Global Healthcare Conference

DURHAM, N.C., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered…

1 year ago

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical…

1 year ago

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America…

1 year ago

Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.

PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating…

1 year ago

U.S. Food and Drug Administration Approves Orphan Drug Designation for Nexcella NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis

FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits…

1 year ago

Skye Bioscience Announces Participation at Upcoming Investor Conferences

San Diego, California--(Newsfile Corp. - September 22, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pharmaceutical…

1 year ago

Pioneering Gynecological Health Startup Famed for Reinventing the Tampon Launches in the U.S.

Female-Founded Startup Debuts World's First CBD Tampon, Diagnostic Tampon and Virtual Period Pain Clinic in the U.S. to Usher in…

1 year ago